Macquarie Group
CRSP icon

Macquarie Group’s CRISPR Therapeutics CRSP Stock Holding History

Macquarie Group’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-27,678
Closed -$1.89M – 1949
2024
Q1 		$1.89M Buy
+27,678
New +$1.98M ﹤0.01% 1238
2023
Q2 		– Sell
-623
Closed -$28K – 1671
2023
Q1 		$28K Sell
623
-39,318
-98% -$1.91M ﹤0.01% 1658
2022
Q4 		$1.62M Sell
39,941
-797,494
-95% -$42.3M ﹤0.01% 1265
2022
Q3 		$54.8M Buy
837,435
+747,413
+830% +$54.2M 0.07% 395
2022
Q2 		$5.47M Buy
90,022
+88,055
+4,477% +$5.18M 0.01% 1013
2022
Q1 		$123 Hold
1,967
– – ﹤0.01% 1898
2021
Q4 		$149K Sell
1,967
-982,923
-100% -$85.9M ﹤0.01% 1830
2021
Q3 		$110M Sell
984,890
-174,877
-15% -$22M 0.09% 274
2021
Q2 		$188M Buy
1,159,767
+1,155,532
+27,285% +$141M 0.15% 153
2021
Q1 		$516K Sell
4,235
-156,100
-97% -$23.6M ﹤0.01% 1528
2020
Q4 		$24.5M Buy
160,335
+93,291
+139% +$11M 0.04% 466
2020
Q3 		$5.61M Sell
67,044
-28,296
-30% -$2.51M 0.01% 799
2020
Q2 		$7.01M Buy
+95,340
New +$5.57M 0.01% 712
2018
Q1 		– Sell
-600
Closed -$14K – 2206
2017
Q4 		$14K Buy
+600
New +$11.4K ﹤0.01% 2229

Other funds holding CRSP

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Macquarie Group's CRSP Position: Q2 2024 in Review

Macquarie Group sold out of CRISPR Therapeutics (CRSP) in Q2 2024, closing a stake of 27,678 shares — an estimated $1.89M sold.

Macquarie Group first reported a position in CRSP in Q4 2017 and held it in 14 quarters. The position peaked at $188M in Q2 2021. 449 funds tracked by Wall St. Rank hold CRSP as of Q2 2024.

  • Macquarie Group reported no remaining CRISPR Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Macquarie Group sold 27,678 CRISPR Therapeutics shares in Q2 2024, an estimated $1.89M.
  • Macquarie Group first reported a position in CRISPR Therapeutics in Q4 2017 and held it in 14 quarters.
  • Macquarie Group's CRISPR Therapeutics position peaked at $188M in Q2 2021.
  • 449 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2024.

Based on Macquarie Group's 13F filing for Q2 2024, filed 9 Aug 2024.